可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Bueno OF, van Rooij E, Molkentin JD, et al. Calcineurin and hypertrophic heart disease: novel insights and remaining questions[J]. Cardiovascular Res, 2002, 53(4):806-821.
[2] Takeda R, Suzuki E, Takahashi M, et al. Calcineurin is critical for sodium-induced neointimal formation in normotensive and hypertensive rats[J]. Am J Physiol Heart Circ Physiol, 2008, 294(6):H2871-H2878.
[3] Sheng H, Zhu J, Wu X, et al. Angiotensin-converting enzyme inhibitor suppress activation of calcineurin in renovascular hypertensive rats[J]. Hypertens Res, 2007, 30(12):1247-1254.
[4] Hill JA, Rothermel B, Yoo KD, et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy[J]. J Biol Chem, 2002, 277(12):10251-10255.
[5] Diedrichs H, Hagemeister J, Chi M, et al. Activation of the calcineurin/NFAT signaling cascade starts early in human hypertrophic myocardium[J]. J Int Med Res, 2007, 35(6):803-818.
[6] Luedde M, Katus HA, Frey N. Novel molecular targets in the treatment of cardiac hypertrophy[J]. Recent Pat Cardiovasc Drug Discov, 2006, 1(1):1-20.
[7] Frank D, Kuhn C, van Eickels M, et al. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy[J]. Circulation, 2007, 116(22):2587-2596.
[8] Faul C, Dhume A, Schecter AD, et al. Protein kinase A, Ca2+/calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between Z-disc and the nucleus of cardiac myocytes[J]. Mol Cell Biol, 2007, 27(23):8215-8227.
[9] Lemmens K, Segers VF, Demolder M, et al. Endogenous inhibitors of hypertrophy in concentric versus eccentric hypertrophy[J]. Eur J Heart Fail, 2007, 9(4):352-356.